Bioscience Animal Health Public Company (BIS) Fair Value & Analysis
Consumer Defensive · TH · Market cap 628M THB
Fair value as of: Jun 24, 2026
From 26 valuation models · updated 5 days ago
Fair value updated Jun 24, 2026 — revised from 3.21 THB to 2.08 THB (−35.2%) since Jun 23, 2026. Share price −4.8% over the past month.
Price vs Fair Value (12 months)
12‑month range 1.83 THB – 2.68 THB · fair‑value band 1.89 THB – 2.60 THB · the 2.02 THB price screens below the 2.08 THB fair value. As of Jun 24, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Bioscience Animal Health Public Company (BIS) currently trades at 2.02 THB, while our model-based Fair Value estimate is 2.08 THB — implying the stock looks roughly 3.0% undervalued today. We read business quality at 93/100 (high quality), in the Consumer Defensive sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.
Over the trailing twelve months, Bioscience Animal Health Public Company generated revenue of 2.3B THB at a net margin of 1.7%. Revenue declined 2.4% year over year. It earns a return on equity of 5.3%. The balance sheet holds a net cash position of 46.1M THB. Fundamentals as of Jun 24, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 24, 2026. TTM = trailing twelve months.
About the company
Bioscience Animal Health Public Company Limited, together with its subsidiaries, manufactures, imports, and distributes pharmaceutical supplies, devices, equipment, and products for livestock and companion animals in Thailand and internationally. The company offers antibiotics, additives, injections, mold inhibitors, water-soluble products, vaccines, hormones, and Bismix B and SD series. It also provides products for livestock and pets, as well as trading services. In addition, the company offers farm production consultant; disease prevention and monitoring; serological diagnostic; farm biosecurity and sanitation; raw material, feed chemical, physical, and mycotoxin analysis; feed formulation; repacking and remixing and OEM Product; and farm human resource and training services. Further, it provides animal health products; nutrition products; diagnostic products, such as test kits and diagnostic medical devices; consulting services about testing method, installation, and laboratory …
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Bioscience Animal Health Public Company reported revenue of 2.3B THB in FY2025 versus 2.0B THB in FY2021, a compound +3.4%/yr. Reported net income was 38.5M THB in FY2025, compounding −14.6%/yr from FY2021.
Open the full interactive analysis →
Similar stocks
6 more Packaged Foods stocks, each showing price versus our Fair Value estimate (as of Jun 24, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Nestlé S.A NSRGF | $97.58 | $65.41 | -33% |
| Foshan Haitian Flavouring and Food Company 603288 | ¥34.03 | ¥23.66 | -30% |
| Nestlé India Limited NESTLEIND | ₹1,402 | ₹362.37 | -74% |
| Grupo Bimbo, S.A. BIMBOA | 57.10 MXN | 45.03 MXN | -21% |
| Uni-President Enterprises Corp 1216 | 73.80 TWD | 61.57 TWD | -17% |
| Britannia Industries Limited BRITANNIA | ₹5,121 | ₹1,374 | -73% |
Explore undervalued stocks
More undervalued Consumer Defensive stocks →
Frequently asked questions
Is Bioscience Animal Health Public Company (BIS) undervalued?
What is the fair value of BIS?
What is the quality score of BIS?
What is the revenue of Bioscience Animal Health Public Company (BIS)?
What is the net profit margin of BIS?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.